Coronado Biosciences Announces Initiation of Investigator-Initiated Study Evaluating TSO in Ulcerative Colitis
Published: Aug 07, 2012
BURLINGTON, Mass., Aug. 7, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today the initiation of an Investigator-Initiated Study (IIS) evaluating TSO (Trichuris suis ova or CNDO-201) for the treatment of ulcerative colitis (UC). The Study is being conducted by the NYU School of Medicine. Dr. Michael A. Poles, Associate Professor of Medicine, Gastroenterology, Microbiology and Pathology and Dr. P'ng Loke, Assistant Professor, Microbiology, from the NYU School of Medicine, are the Principal Investigators of the trial. Dr. Loke has acted as a scientific advisor to the company and in this role has received minimal compensation for his services.